More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It
In Brief: NCI Can Proceed With Grant, Contract Awards At Full FY 1978 Level; Rundles Heads ACS
Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans
First analysis From Profiles Reveal New Data On Centers
New research Suggested For Immunobiology
NCI Offers Chlorozotocin
To Industry for Development, NDA
Drug Development Gets Extra $500,000
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final









